Tuberculosis medical therapy special conditions: Difference between revisions
Jump to navigation
Jump to search
Joao Silva (talk | contribs) |
Joao Silva (talk | contribs) |
||
| Line 6: | Line 6: | ||
==HIV Coinfection== | ==HIV Coinfection== | ||
Depending on the treatment status of | Depending on the treatment status of each patient, different approaches may be taken:<ref name="pmid19105873">{{cite journal| author=Harries AD, Zachariah R, Lawn SD| title=Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. | journal=Int J Tuberc Lung Dis | year= 2009 | volume= 13 | issue= 1 | pages= 6-16 | pmid=19105873 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19105873 }} </ref> | ||
===Patients Not Taking ART=== | ===Patients Not Taking ART=== | ||
* After the diagnosis of TB in an HIV-positive patient, not taking [[antiretroviral therapy]] ([[ART]]), the priority is to initiate treatment for TB, along with [[co-trimoxazole]] and [[ART]]. | * After the diagnosis of TB in an HIV-positive patient, not taking [[antiretroviral therapy]] ([[ART]]), the priority is to initiate treatment for TB, along with [[co-trimoxazole]] and [[ART]]. | ||
* These patients should be treated with the same regimen as | * These patients should be treated with the same regimen as HIV-negative patients, with the exception that the optional 3 times/week of intensive phase treatment, is mandatory for HIV-positive patients. This leads to a decrease in the incidence of TB relapse and resistance to rifampicin , often seen in HIV-positive patients.<ref name="pmid20353364">{{cite journal| author=Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD et al.| title=Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. | journal=Clin Infect Dis | year= 2010 | volume= 50 | issue= 9 | pages= 1288-99 | pmid=20353364 | doi=10.1086/651686 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20353364 }} </ref><ref name="WHO 2013"> {{cite web| url=http://www.who.int/tb/publications/tb_treatmentguidelines/en/| title=2013 WHO Treatment of Tuberculosis: Guidelines for National Programmes (4th Edition) }}</ref> | ||
<!-- | <!-- | ||
Revision as of 19:19, 17 September 2014
|
Tuberculosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tuberculosis medical therapy special conditions On the Web |
|
American Roentgen Ray Society Images of Tuberculosis medical therapy special conditions |
|
Risk calculators and risk factors for Tuberculosis medical therapy special conditions |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
HIV Coinfection
Depending on the treatment status of each patient, different approaches may be taken:[1]
Patients Not Taking ART
- After the diagnosis of TB in an HIV-positive patient, not taking antiretroviral therapy (ART), the priority is to initiate treatment for TB, along with co-trimoxazole and ART.
- These patients should be treated with the same regimen as HIV-negative patients, with the exception that the optional 3 times/week of intensive phase treatment, is mandatory for HIV-positive patients. This leads to a decrease in the incidence of TB relapse and resistance to rifampicin , often seen in HIV-positive patients.[2][3]
Patients Taking ART
Extrapulmonary
Tuberculous Lymphadenitis
Skeletal Tuberculosis
Tuberculous Meningitis
Miliary Tuberculosis
Tuberculosis Peritonitis
Tuberculous Pericarditis
Renal Tuberculosis
Liver Disease
Referencies
- ↑ Harries AD, Zachariah R, Lawn SD (2009). "Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa". Int J Tuberc Lung Dis. 13 (1): 6–16. PMID 19105873.
- ↑ Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD; et al. (2010). "Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis". Clin Infect Dis. 50 (9): 1288–99. doi:10.1086/651686. PMID 20353364.
- ↑ "2013 WHO Treatment of Tuberculosis: Guidelines for National Programmes (4th Edition)".